Real-world Outcomes of Trifluridine/Tipiracil With or Without Bevacizumab in Metastatic Colorectal Cancer: A Retrospective Cohort Study
Anticancer Research · 2026
DOI: 10.21873/anticanres.18399 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Anticancer Research, 2026. Verfasst von Tetsuro Kawazoe und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; kzoe922@gmail.com. Hauptthemen laut MEDLINE: Bevacizumab, Colorectal Neoplasms, Trifluridine, Thymine.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; kzoe922@gmail.com.
- Department of Advanced Medicine and Innovative Technology, Kyushu University Hospital, Fukuoka, Japan.
- Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Zitieren
APA
Kawazoe, T., Ando, K., Ryujin, K., Nambara, S., Tsuda, Y., Nakanoko, T., Oki, E., & Yoshizumi, T. (2026). Real-world Outcomes of Trifluridine/Tipiracil With or Without Bevacizumab in Metastatic Colorectal Cancer: A Retrospective Cohort Study. Anticancer Research. https://doi.org/10.21873/anticanres.18399
Vancouver
Kawazoe T, Ando K, Ryujin K, Nambara S, Tsuda Y, Nakanoko T, et al. Real-world Outcomes of Trifluridine/Tipiracil With or Without Bevacizumab in Metastatic Colorectal Cancer: A Retrospective Cohort Study. Anticancer Research. 2026. doi:10.21873/anticanres.18399
BibTeX
@article{Kawazoe2026,
author = {Kawazoe, Tetsuro and Ando, Koji and Ryujin, Keiichiro and Nambara, Sho and Tsuda, Yasuo and Nakanoko, Tomonori and Oki, Eiji and Yoshizumi, Tomoharu},
title = {Real-world Outcomes of Trifluridine/Tipiracil With or Without Bevacizumab in Metastatic Colorectal Cancer: A Retrospective Cohort Study},
journal = {Anticancer Research},
year = {2026},
doi = {10.21873/anticanres.18399}
}
EUVIMED